Clinical Trial: A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07038005) titled 'A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors' on June 17.

Brief Summary: This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.

Study Start Date: July 13

Study Type: INTERVENTIONAL

Condition: Advanced Malignant Tumors

Intervention: DRUG: SPGL008

Biological product

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

Disclaimer: Curated by HT Syndication....